Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Orsini Diego, Potestio Luca, Fargnoli Maria Concetta, Narcisi Alessandra, Ibba Luciano, Assorgi Chiara, Balato Anna, Burlando Martina, Campanati Anna, Carrera Carlo Giovanni, Carugno Andrea, Costanzo Antonio, Cozzani Emanuele, Dapavo Paolo, Dattola Annunziata, Di Brizzi Eugenia Veronica, Di Tano Antonio, Dini Valentina, Gaiani Francesca Maria, Gargiulo Luigi, Girolomoni Giampiero, Guarneri Claudio, Lasagni Claudia, Loconsole Francesco, Malagoli Piergiorgio, Marzano Angelo Valerio, Mastorino Luca, Maurelli Martina, Messina Francesco, Michelucci Alessandra, Pellacani Giovanni, Ribero Simone, Travaglini Massimo, Trovato Emanuele, Zerbinati Nicola, Megna Matteo
Аннотация
OBJECTIVES: To evaluate the cumulative clinical benefits of biologic therapies in patients with moderate-to-severe plaque psoriasis in a real-world Italian multicentre setting.
METHODS: This multicentre retrospective real-life study included patients treated with bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab or ustekinumab at 23 Italian referral centres. Cumulative benefit was assessed by the AUC of PASI 100 (100% improvement from baseline) from week 0 to week 52, and days free of disease (PASI 100). Analyses included subgroup evaluations by biologic-naive status and baseline PASI (≤ 10 vs. > 10).
RESULTS: Among 1017 patients, bimekizumab showed the highest cumulative clinical benefit, with a mean of 203 days free of disease. It was significantly superior to guselkumab (P < 0.05), secukinumab (P < 0.01), ustekinumab (P < 0.01) and tildrakizumab (P < 0.001). The advantage was consistent across subgroups, with 216 days free of disease in biologic-naive and 184 in biologic-experienced patients. No significant differences were found between bimekizumab and ixekizumab, brodalumab or risankizumab.
CONCLUSIONS: In this multicentre real-life study, bimekizumab showed exploratory evidence of the cumulative clinical benefit of biologics in moderate-to-severe psoriasis. These findings highlight the importance of cumulative endpoints and individualized treatment strategies in daily practice.